ACRS - Aclaris Therapeutics EPS misses by $0.07 misses on revenue November, 02 2021 07:40 AM Aclaris Therapeutics Inc. Aclaris Therapeutics (NASDAQ:ACRS): Q3 GAAP EPS of -$0.35 misses by $0.07. Revenue of $1.65M (+17.9% Y/Y) misses by $0.12M. Press Release Shares -2.11% PM For further details see: Aclaris Therapeutics EPS misses by $0.07, misses on revenue